COMPARATIVE ANALYSIS OF THE EFFECTIVENESS OF OLD AND NEW TB DRUGS IN THE TREATMENT OF PULMONARY TUBERCULOSIS
Article Sidebar
Drug Regimens,
Pyrazinamide,
Rifampin,
BPal Regimen,
Treatment Adherence,
Drug-Resistant TB
Main Article Content
Abstract
Background. The availability of effective drug regimens of Pulmonary tuberculosis (TB) poses a global health challenge. Traditional first-line therapies-isoniazid, rifampicin, pyrazinamide, and ethambutol-remain the cornerstone of TB management due to their accessibility and documented cure rates exceeding 85%. Nevertheless, limitations such as variable drug metabolism, patient non-adherence, and the emergence of multidrug-resistant strains have prompted evaluation of newer treatment combinations to optimize efficacy, safety, and duration. The purpose was to compare the effectiveness of older first-line tuberculosis (TB) drug regimens with newer therapeutic regimens in the treatment of pulmonary tuberculosis.
Research Method. This narrative review synthesizes findings from five peer-reviewed studies comparing the effectiveness and safety profiles of conventional and novel TB drug regimens. The review focused on regimen composition, treatment duration, bacteriological clearance, hepatotoxicity, and patient adherence outcomes.
Findings. The inclusion of pyrazinamide in six-month regimens significantly accelerated bacterial clearance without increasing hepatic toxicity compared to traditional nine-month isoniazid–rifampicin regimens. Additionally, shorter rifampin-based regimens for latent TB demonstrated higher treatment completion rates and fewer adverse effects than isoniazid monotherapy. Emerging regimens, such as fluoroquinolone-based HRM therapies and the novel BPaL combination (bedaquiline, pretomanid, and linezolid), yielded comparable or improved outcomes, with BPaL achieving success rates up to 93% in drug-resistant TB cases.
Conclusion. Current evidence supports the strategic adaptation of TB therapy to balance efficacy, tolerability, and treatment duration. Incorporating newer drug combinations, particularly for drug-resistant TB, enhances adherence and clinical outcomes, underscoring the need for individualized treatment protocols aligned with evolving resistance patterns and patient profiles.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
P. Denti et al., “Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania,” journals.plos.orgP Denti, K Jeremiah, E Chigutsa, D Faurholt-Jepsen, G Pray. N Range, S CastelPloS one, 2015•journals.plos.org, vol. 10, no. 10, 2015, doi: 10.1371/JOURNAL.PONE.0141002.
F. Tumiwa, A. Pondaa, and A. R. C. Langingi, “Faktor-Faktor Determinan yang Berhubungan dengan Kejadian Ulang (Relaps) Pada Penderita TB Paru di RSUD X,” Aksara J. Ilmu Pendidik. Nonform., vol. 9, no. 1, pp. 791–802, May 2023, [Online]. Available: https://ejurnal.pps.ung.ac.id/index.php/Aksara/article/view/1725
Y. Shang et al., “A Prospective, Randomized Controlled Study for the Efficacy and Safety of the Substitution of Pyrazinamide and Ethambutol With Moxifloxacin During the,” May 2021, doi: 10.21203/RS.3.RS-352867/V1.
C. Jani et al., “TLR2 is non-redundant in the population and subpopulation responses to Mycobacterium tuberculosis in macrophages and in vivo,” mSystems, pp. e00052-23, Jun. 2023, doi: 10.1128/msystems.00052-23.
A. Somner, B. T. A.-B. J. of D. of, and undefined 1981, “A controlled trial of six months chemotherapy in pulmonary tuberculosis: first report: results during chemotherapy,” Elsevier, vol. 75, no. 2, pp. 141–153, 1981, doi: 10.1016/0007-0971(81)90046-2.
W. H. Organization, “World Health Organization Global Tuberculosis Report 2020,” World Heal. Organ., vol. 232, 2020.
?. Kizilta? and A. Babalik, “Tuberculosis: An Overview,” in Airway Diseases, C. Cingi, A. Yorganc?o?lu, N. Bayar Muluk, and A. A. Cruz, Eds., Cham: Springer International Publishing, 2023, pp. 635–659. [Online]. Available: https://link.springer.com/10.1007/978-3-031-22483-6_40-1
D. Menzies et al., “Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults,” Mass Med. SocD Menzies, M Adjobimey, R Ruslami, A Trajman, O Sow, H Kim, J Obeng Baah, GB Marks. Engl. J. Med. 2018•Mass Med. Soc, vol. 379, no. 5, pp. 440–453, Aug. 2018, doi: 10.1056/NEJMOA1714283.
W. H. Organization, Global tuberculosis report 2021: supplementary material. World Health Organization, 2022. [Online]. Available: https://books.google.com/books?hl=en&lr=&id=DHkOEQAAQBAJ&oi=fnd&pg=PA1&dq=Global+Tuberculosis+Report+2022.+1st+ed.+World+Health+Organization%3B+2022&ots=lf6ldEnHqi&sig=-FODQpsgdPE9Y5hZpEqJqzXPdnc
R. Ratnawati and M. Arifin, “The Relantionship Characteristic and Relaps in Pulmonary Tuberculosis Patients at RSI PKU Muhammadiyah Pekajangan Pekalongan,” May 2022, pp. 624–629. [Online]. Available: https://repository.urecol.org/index.php/proceeding/article/view/2115
E. Mortaz et al., “Interaction of Pattern Recognition Receptors with Mycobacterium Tuberculosis,” J. Clin. Immunol., vol. 35, no. 1, pp. 1–10, Jun. 2015, doi: 10.1007/s10875-014-0103-7.
F. Conradie et al., “Bedaquiline–pretomanid–linezolid regimens for drug-resistant tuberculosis,” Mass Med. SocF Conradie, TR Bagdasaryan, S Borisov, P Howell, L Mikiashvili, N Ngubane, A SamoilovaNew Engl. J. Med. 2022•Mass Med. Soc, vol. 387, no. 9, pp. 810–823, Sep. 2022, doi: 10.1056/NEJMOA2119430.
M. Aris, “Hubungan Pengetahuan dan Sikap terhadap Perilaku Pencegahan TB Paru di Wilayah Kerja Puskesmas Palakka Bupaten Barru,” Media Publ. Promosi Kesehat. Indones., vol. 6, no. 1, pp. 175–182, May 2023, [Online]. Available: https://jurnal.unismuhpalu.ac.id/index.php/MPPKI/article/view/2989
A. Isranugraha and A. Nur, “Gambaran Tingkat Pengetahuan Dan Sikap Masyarakat Terhadap Upaya Pencegahan Penyakit Tb Paru Di Puskesmas Kalumata,” Kieraha Med. J., vol. 3, no. 1, pp. 47–56, May 2021, [Online]. Available: https://ejournal.unkhair.ac.id/index.php/kmj/article/view/3270
F. G. Wilder, B. Cangut, R. Jindani, O. Abioye, and N. Florez, “Lung cancer screening among minority groups: Identifying gaps in screening and opportunities for intervention,” JTCVS open, vol. 21, pp. 341–348, Mar. 2024, [Online]. Available: https://www.jtcvsopen.org/article/S2666-2736(24)00181-5/fulltext
A. Booth et al., “Taking account of context in systematic reviews and guidelines considering a complexity perspective,” gh.bmj.comA Booth, G Moore, K Flemming, R Garside, N Roll. Ö Tunçalp, J NoyesBMJ Glob. Heal. 2019•gh.bmj.com, vol. 4, p. 840, 2019, doi: 10.1136/bmjgh-2018-000840.
B. Rasmussen, L. U.-D. and Rehabilitation, and undefined 2016, “Establishing well-being after hip fracture: a systematic review and meta-synthesis,” Taylor Fr., vol. 38, no. 26, pp. 2515–2529, Dec. 2016, doi: 10.3109/09638288.2016.1138552.